Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is the world's largest generic medicines manufacturer, headquartered in Petah Tikva, Israel, and founded in 1901. It is a publicly traded company with no controlling shareholder. Teva reported revenues of $16,544 million in 2024 (per its 20-F annual report) and states roughly 37,000–43,000 employees globally across more than 60 markets, with over 50–70 manufacturing sites.
Operations. Teva develops, manufactures and distributes generic drugs across nearly every therapeutic area; it also sells specialty/innovative medicines, active pharmaceutical ingredients (Teva API), biosimilars and over-the-counter products. Key branded assets include Ajovy (migraine), Austedo (tardive dyskinesia/Huntington's chorea), Uzedy (schizophrenia) and Copaxone (multiple sclerosis). Its U.S. operations include Teva Pharmaceuticals USA, Inc., based in Parsippany, New Jersey.
Litigation posture. Teva is an operating company, not an assertion entity. Both tracked cases show it as a defendant (0 as plaintiff), consistent with its role as a frequent target of Hatch-Waxman/ANDA patent suits brought by branded-drug holders. Both cases were filed in the U.S. District Court for the District of New Jersey — a common venue for Paragraph IV litigation because Teva's U.S. generics operations are based there, not a plaintiff-friendly NPE forum.
Notable cases. Both tracked matters are Adapt Pharma Operations Limited et al. v. Teva Pharmaceuticals USA, Inc. et al. (D.N.J.), filed 2016-11-26 and 2018-04-09. They concern Adapt/Opiant's NARCAN nasal-spray patents (U.S. 9,468,747; 9,561,177; 9,629,965; 9,775,838) and Teva's ANDA to market a generic 4 mg naloxone nasal spray. Teva stipulated to infringement and challenged validity; the district court held the asserted claims obvious, and the Federal Circuit affirmed in Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 25 F.4th 1354 (Fed. Cir. 2022). The 2018 filing appears to be a follow-on action involving an additional patent in the same family.